Who is sponsoring NCT00824252?

NCT00824252 is sponsored by M.D. Anderson Cancer Center.

What drugs are being tested in NCT00824252?

Interventions in NCT00824252: Questionnaires & Study Visit.

What condition does NCT00824252 study?

NCT00824252 studies Head And Neck Cancer.

Is NCT00824252 still recruiting?

NCT00824252 is currently completed. Last updated 8 March 2022.

Last reviewed 2022-03-08 · How we verify

NCT00824252

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spousal Support in Head and Neck Cancer

Completed Last updated 8 March 2022

What this trial tests

trial testing Questionnaires & Study Visit in Head And Neck Cancer in 361 participants. Completed in 23 February 2022.

Timeline

8 December 2008

Primary endpoint
23 February 2022

23 February 2022

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Status	Completed
Study type	OBSERVATIONAL
Enrollment	361
Start date	8 December 2008
Primary completion	23 February 2022
Estimated completion	23 February 2022
Sites	1 location across United States

Drugs / interventions tested

Questionnaires & Study Visit

Conditions studied

Head And Neck Cancer — all drugs for Head And Neck Cancer →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Head And Neck Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this research study is to look at social and relationship factors that may affect the quality of life of patients with head and neck cancer and their spouses.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Head And Neck Cancer

Currently open trials in the same condition.

NCT01266044 — Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia · Phase 3 · active not recruiting

Other M.D. Anderson Cancer Center trials

Trials by the same sponsor.

NCT07053020 — A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukem · Phase 1, PHASE2 · not yet recruiting
NCT07052994 — A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and · Phase 1 · not yet recruiting
NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
NCT07162480 — Phase II Trial of Puxitatug Samrotecan (AZD8205) in Advanced, Recurrent or Metastatic (R/M) Aggressive Adenoid Cystic Ca · Phase 2 · not yet recruiting
NCT07076498 — Engineered HSV-1 M032 for the Treatment of Children and Adults With Newly Diagnosed Diffuse Midline Glioma After Standar · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00824252 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by M.D. Anderson Cancer Center
Last refreshed: 8 March 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00824252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing